Evaluating ODX for treating Multiple Myeloma

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

This study is testing a new treatment called ODX to see if it is safe and effective for people with relapsed or refractory multiple myeloma.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: DexTech Medical AB (Industry-sponsored)
• Drugs / interventions: denosumab, chemotherapy, radiation
• Locations: 2 sites (Stockholm and 1 other locations)
• Trial ID: NCT06616389 on ClinicalTrials.gov

What this trial studies

This phase I/IIa trial is a multi-center, open-label study designed to assess the safety and biological efficacy of ODX (OsteoDex) in patients with relapsed or refractory multiple myeloma. Participants will receive up to 7 doses of ODX at 2-week intervals, with each dose cohort consisting of 4 subjects. The primary objective is to determine the safety and tolerability of ODX, while secondary objectives include evaluating its preliminary efficacy based on established response criteria and serum biomarkers. Follow-up visits will occur 2 weeks after the last dose to monitor outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a documented diagnosis of relapsed or refractory multiple myeloma who have received 1-5 prior lines of therapy.

Not a fit: Patients who have not received prior treatments or those with non-measurable disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with relapsed or refractory multiple myeloma.

How similar studies have performed: While this approach is being evaluated in this trial, similar studies targeting multiple myeloma have shown promise, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

* 1\. Subject (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF).

  2\. Documented diagnosis av multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria.

  3\. Measurable disease defined as either:
  * Serum monoclonal paraprotein (M-protein) level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
  * Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.

    4\. Subjects must have received 1-5 prior lines of therapy including a PI, IMiD and CD38 antibody\*.

    \*Patients eligible for inclusion should have received said treatments, i.e., according to clinical routine, unless contraindicated due to induced morbidity.

    5\. Subjects must have documented evidence of progressive disease based on the IMWG criteria on or after their last line of therapy.

    6\. Performance status ECOG 0-2 7. Laboratory requirements:

Haematology:

Neutrophils ≥ 1.0 x 109/l Hemoglobin ≥ 80 g/l Platelets ≥ 50 x 109/l

Hepatic function:

Total S/P-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN

Renal function:

S/P-creatinine ≤ 1.5 times ULN

Electrolytes:

S/P-sodium, S/P-potassium, S/P-calcium corrected for S/P albumin , S/P-phosphate, and S/P magnesium, all within normal ranges. At the discretion of the Investigator, supplements may be given to correct these values, in which case electrolytes must be shown to be within normal ranges before inclusion into the study.

8\. No evidence (\< 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).

9\. Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Concurrent use of other anti-cancer agents/treatments.
2. Any treatment modalities involving chemotherapy, radiation, or major surgery within 4 weeks prior to treatment in this study.
3. Simultaneous participation in any other study involving investigational drugs or having participated in an investigational study less than 4 weeks prior to start of study treatment.
4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he or she participates in the study.
5. Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
6. Plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome.
7. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug.
8. Treatment with bisphosphonates or denosumab within 6 weeks prior to first dose of study medication.
9. Male subjects not willing to use condom to prevent pregnancy and drug exposure of a fertile female partner and refrain from donating sperm from the date of the first dose until the end of study treatment.
10. Pregnant or breastfeeding females.
11. Female subjects of childbearing potential\*\* not willing to use a contraceptive method with a failure rate of \< 1% to prevent pregnancy during study treatment. Highly effective birth control methods include:

    * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      * oral
      * intravaginal
      * transdermal
    * progestogen-only hormonal contraception associated with inhibition of ovulation:

      * oral
      * injectable
      * implantable
    * intrauterine device
    * intrauterine hormone-releasing system (for example, progestin-releasing coil)
    * vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
    * bilateral tubal occlusion or hysterectomy. \*\*Female subjects are considered of non-childbearing potential if they are pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as at least 12 months of amenorrhea.
12. Subjects in which pre-medication with dexamethasone, antihistamine, and paracetamol would be contraindicated.

Where this trial is running

Stockholm and 1 other locations

• Karolinska Universitetssjukhuset Huddinge Cancerstudieenheten M62 — Stockholm, Sweden (Recruiting)
• Uddevalla Sjukhus, Hematologens dagvård — Uddevalla, Sweden (Recruiting)

Study contacts

• Study coordinator: Anders Holmberg, Med DR

Conditions Multiple Myeloma